骨髓增殖性肿瘤相关内脏静脉血栓518例国际回顾性研究
该国际回顾性队列研究纳入518例MPN相关内脏静脉血栓(SVT)患者,与1628例按疾病亚型匹配的对照MPN患者比较。MPN-SVT患者较年轻且女性居多,JAK2V617F突变率90.2%,SVT复发率1.6/100患者年;维生素K拮抗剂(VKA)使复发率减半(OR 0.48),而细胞减灭治疗无此效应(OR 0.96),食管静脉曲张是唯一独立的大出血预测因素(OR 17.4)。
要点
- MPN-SVT患者中JAK2V617F突变率高达90.2%,38.6%合并其他高凝状态。
- VKA可降低SVT复发(OR 0.48),细胞减灭治疗未显示降低复发(OR 0.96)。
- 食管静脉曲张是MPN-SVT患者大出血的唯一独立预测因素(OR 17.4)。
核心结论
- 在迄今最大的MPN-SVT当代队列中,VKA被证实能有效预防复发且安全,而细胞减灭治疗未见此效应。
- 食管静脉曲张是MPN-SVT患者大出血的主要风险因素,应作为重要治疗目标。
研究设计与样本
- 国际工作组MPN研究与治疗(IWG-MRT)和AGIMM框架下的回顾性队列研究。
- 共收集518例MPN-SVT病例,与1628例按疾病亚型匹配的未选择对照MPN人群比较。
主要发现
- MPN-SVT患者较对照更年轻(中位44岁)且女性比例更高;PV(37.1%)和ET(34.4%)最常见。
- JAK2V617F突变率为90.2%,38.6%的病例合并其他高凝状态。
- SVT复发率为1.6/100患者年;VKA使复发率减半(OR 0.48),细胞减灭治疗OR 0.96。
- 食管静脉曲张是大出血的唯一独立预测因素(OR 17.4)。
- MPN-SVT患者后续血管事件以静脉血栓为主;PMF伴SVT者IPSS较低且生存显著长于对照,PV生存未受影响,ET略有降低。
关键数值与推荐
- VKA预防SVT复发的OR为0.48,细胞减灭治疗OR为0.96。
- 食管静脉曲张预测大出血的OR为17.4。
- MPN-SVT复发率为1.6/100患者年。
- MPN-SVT患者中JAK2V617F突变率90.2%,PV占37.1%,ET占34.4%。
临床怎么用
- 对于MPN相关SVT患者,应考虑使用VKA预防血栓复发。
- 应筛查和管理食管静脉曲张以降低大出血风险。
- 细胞减灭治疗在预防SVT复发方面的作用未得到证实。
局限性
- 回顾性研究设计可能引入选择偏倚和信息偏倚。
- 对照人群为未选择的MPN患者,匹配仅基于疾病亚型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative Neoplasms (MPN) course can be complicated by thrombosis involving unusual sites as the splanchnic veins (SVT). Their management is challenging, given their composite vascular risk. We performed a retrospective, cohort study in the framework of the International Working Group for MPN Research and Treatment (IWG-MRT), and AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM). A total of 518 MPN-SVT cases were collected and compared with 1628 unselected, control MPN population, matched for disease subtype. Those with MPN-SVT were younger (median 44 years) and enriched in females compared to controls; PV (37.1%) and ET (34.4%) were the most frequent diagnoses. JAK2V617F mutation was highly prevalent (90.2%), and 38.6% of cases had an additional hypercoagulable disorder. SVT recurrence rate was 1.6 per 100 patient-years. Vitamin K-antagonists (VKA) halved the incidence of recurrence (OR 0.48), unlike cytoreduction (OR 0.96), and were not associated with overall or gastrointestinal bleeding in multivariable analysis. Esophageal varices were the only independent predictor for major bleeding (OR 17.4). Among MPN-SVT, risk of subsequent vascular events was skewed towards venous thromboses compared to controls. However, MPN-SVT clinical course was overall benign: SVT were enriched in PMF with lower IPSS, resulting in significantly longer survival than controls; survival was not affected in PV and slightly reduced in ET. MPN-U with SVT (n = 55) showed a particularly indolent phenotype, with no signs of disease evolution. In the to-date largest, contemporary cohort of MPN-SVT, VKA were confirmed effective in preventing recurrence, unlike cytoreduction, and safe; the major risk factor for bleeding was esophageal varices that therefore represent a major therapeutic target.
引用
- Sant'Antonio E, Guglielmelli P, Pieri L, et al. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. Am J Hematol. 2019. PMID: 31721282. doi:10.1002/ajh.25677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。